stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio non interventistico di real-life sulla terapia di prima linea dei pazienti affetti da leucemia plasmacellulare primitiva eleggibili a trapianto (Studio Giorgione).

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
VI-MM-03 (GIORGIONE)
Codice EudraCT
NP
Sponsor/Promotore
Ospedale San Bortolo di Vicenza
Tipologia
Osservazionale
Fase
.
Unità Operativa
Oncoematologia - CF
Principal Investigator

Efficacia dei regimi basati su Isatuximab nel mieloma multiplo Recidivato/Refrattario in presenza di 1q21+

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
Isa_1q21+
Codice EudraCT
NP
Sponsor/Promotore
IRCCS Azienda-Ospedaliero Universitaria di Bologna
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Regimi di salvataggio in pazienti refrattari a Lenalidomide e agli anticorpi monoclonali antiCD38: evidenze dalla real-life (DARE-MM study: DAratumumab and REvlimid REfractory MM)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
DARE-MM
Codice EudraCT
NP
Sponsor/Promotore
Fondazione IRCCS Policlinico San Matteo
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio osservazionale multicentrico retrospettivo e prospettico sull’impatto della terapia di induzione con schema daratumumab- bortezomib- thalidomide – desametasone sulla raccolta di cellule staminali emopoietiche ed engraftment nei pazienti affetti da mieloma multiplo eleggibili a trapianto

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
PRIMULA
Codice EudraCT
NP
Sponsor/Promotore
Azienda Ospedaliero- Universitaria Policlinico di Bari
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top